Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

Posted: March 25, 2022 at 2:21 am

Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi)

Continued here:
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

Related Posts